Ke-Sheng Wang1, Lingjun Zuo2, Daniel Owusu1, Yue Pan3, Xingguang Luo4. 1. Department of Biostatistics and Epidemiology, College of Public Health, East Tennessee State University, Johnson City, TN, USA. 2. Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA. 3. Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami, FL, USA. 4. Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA; Biological Psychiatry Research Center, Beijing Huilongguan Hospital, Beijing, China.
Abstract
BACKGROUND: Epidemiological studies have shown that there is a reduced risk of prostate cancer among persons diagnosed with schizophrenia (SCZ). However, the mechanism of such relationship is not clear. The reduced incidence of cancer observed in SCZ patients may be related to differences in genetic background. Recently, the JAZF1 gene is found to be associated with prostate cancer and type 2 diabetes. However, no study has focused on the association of JAZF1 with the risk of SCZ. METHODS: We examined genetic associations of 118 single-nucleotide polymorphisms (SNPs) within the JAZF1 gene with SCZ using one European American (EA) sample of 1,149 cases and 1,347 controls. Logistic regression analysis of SCZ as a binary trait was performed using PLINK software. RESULTS: The most significant association with SCZ was observed with rs10258132 (p = 0.0011); while the next best signal was rs17156259 (p = 0.0031). The third best associated SNP was rs7791865 (p = 0.00889). In addition, haplotype analyses revealed that the A-C haplotype from rs10244184 and rs10258132 was associated with SCZ (p = 0.00093); and the G-G haplotype from rs17156238 and rs17156259 was associated with SCZ (p = 0.00455). CONCLUSION: These findings provide evidence of several genetic variants in JAZF1 gene influencing the risk of SCZ and will serve as a resource for replication in other populations.
BACKGROUND: Epidemiological studies have shown that there is a reduced risk of prostate cancer among persons diagnosed with schizophrenia (SCZ). However, the mechanism of such relationship is not clear. The reduced incidence of cancer observed in SCZ patients may be related to differences in genetic background. Recently, the JAZF1 gene is found to be associated with prostate cancer and type 2 diabetes. However, no study has focused on the association of JAZF1 with the risk of SCZ. METHODS: We examined genetic associations of 118 single-nucleotide polymorphisms (SNPs) within the JAZF1 gene with SCZ using one European American (EA) sample of 1,149 cases and 1,347 controls. Logistic regression analysis of SCZ as a binary trait was performed using PLINK software. RESULTS: The most significant association with SCZ was observed with rs10258132 (p = 0.0011); while the next best signal was rs17156259 (p = 0.0031). The third best associated SNP was rs7791865 (p = 0.00889). In addition, haplotype analyses revealed that the A-C haplotype from rs10244184 and rs10258132 was associated with SCZ (p = 0.00093); and the G-G haplotype from rs17156238 and rs17156259 was associated with SCZ (p = 0.00455). CONCLUSION: These findings provide evidence of several genetic variants in JAZF1 gene influencing the risk of SCZ and will serve as a resource for replication in other populations.
Entities:
Keywords:
JAZF1; Pleiotropy; Prostate cancer; Schizophrenia; Single nucleotide polymorphism
Authors: Ludmila Prokunina-Olsson; Yi-Ping Fu; Wei Tang; Kevin B Jacobs; Richard B Hayes; Peter Kraft; Sonja I Berndt; Sholom Wacholder; Kai Yu; Amy Hutchinson; Heather Spencer Feigelson; Michael J Thun; W Ryan Diver; Demetrius Albanes; Jarmo Virtamo; Stephanie Weinstein; Fredrick R Schumacher; Geraldine Cancel-Tassin; Olivier Cussenot; Antoine Valeri; Gerald L Andriole; E David Crawford; Christopher A Haiman; Brian E Henderson; Laurence Kolonel; Loic Le Marchand; Afshan Siddiq; Elio Riboli; Ruth Travis; Rudolf Kaaks; William B Isaacs; Sarah D Isaacs; Henrik Grönberg; Fredrik Wiklund; Jianfeng Xu; Lars J Vatten; Kristian Hveem; Merethe Kumle; Margaret Tucker; Robert N Hoover; Joseph F Fraumeni; David J Hunter; Gilles Thomas; Nilanjan Chatterjee; Stephen J Chanock; Meredith Yeager Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-04-20 Impact factor: 4.254
Authors: Jianxin Shi; Douglas F Levinson; Jubao Duan; Alan R Sanders; Yonglan Zheng; Itsik Pe'er; Frank Dudbridge; Peter A Holmans; Alice S Whittemore; Bryan J Mowry; Ann Olincy; Farooq Amin; C Robert Cloninger; Jeremy M Silverman; Nancy G Buccola; William F Byerley; Donald W Black; Raymond R Crowe; Jorge R Oksenberg; Daniel B Mirel; Kenneth S Kendler; Robert Freedman; Pablo V Gejman Journal: Nature Date: 2009-07-01 Impact factor: 49.962
Authors: Mitchell J Machiela; Sara Lindström; Naomi E Allen; Christopher A Haiman; Demetrius Albanes; Aurelio Barricarte; Sonja I Berndt; H Bas Bueno-de-Mesquita; Stephen Chanock; J Michael Gaziano; Susan M Gapstur; Edward Giovannucci; Brian E Henderson; Eric J Jacobs; Laurence N Kolonel; Vittorio Krogh; Jing Ma; Meir J Stampfer; Victoria L Stevens; Daniel O Stram; Anne Tjønneland; Ruth Travis; Walter C Willett; David J Hunter; Loic Le Marchand; Peter Kraft Journal: Am J Epidemiol Date: 2012-11-28 Impact factor: 4.897
Authors: Nicole Soranzo; Fernando Rivadeneira; Usha Chinappen-Horsley; Ida Malkina; J Brent Richards; Naomi Hammond; Lisette Stolk; Alexandra Nica; Michael Inouye; Albert Hofman; Jonathan Stephens; Eleanor Wheeler; Pascal Arp; Rhian Gwilliam; P Mila Jhamai; Simon Potter; Amy Chaney; Mohammed J R Ghori; Radhi Ravindrarajah; Sergey Ermakov; Karol Estrada; Huibert A P Pols; Frances M Williams; Wendy L McArdle; Joyce B van Meurs; Ruth J F Loos; Emmanouil T Dermitzakis; Kourosh R Ahmadi; Deborah J Hart; Willem H Ouwehand; Nicholas J Wareham; Inês Barroso; Manjinder S Sandhu; David P Strachan; Gregory Livshits; Timothy D Spector; André G Uitterlinden; Panos Deloukas Journal: PLoS Genet Date: 2009-04-03 Impact factor: 5.917